Table 1.

Characteristics of studies on the effect of SSRIs on depression in patients on chronic hemodialysis. Data are expressed as mean ± SD. CBT, cognitive behavioral therapy; BDI, Beck Depression Inventory; BSI, Brief Symptom Inventory; MADRS, Montgomery Asberg Depression Rating Scale; HADS, Hospital Anxiety and Depression Scale (HADS); HAMD, Hamilton Depression Rating Scale; QIDS-C, Quick Inventory of Depressive Symptomatology—Clinician Rated; RCT, randomized controlled trial; NR, not reported.

	Country	Type of Study	Number of Patients (Intervention: Placebo)	Age (yrs)	Sex	Race	Intervention	Duration	SSRI Dosage
Blumenfield et al., 1997 [13]	USA	RCT	13 Fluoxetine: n = 6 Placebo: n = 7	NR	NR	NR	Fluoxetine vs. placebo	8 weeks	20 mg/daily
Yazici et al., 2012 [19]	Turkey	RCT	58 Escitalopram: n = 30 Placebo: n = 28	51	Males 52%	NR	Escitalopram vs. placebo	8 weeks	20 mg/daily
Taraz et al., 2013 [18]	Iran	RCT	43 Sertraline: n = 21 Placebo: n = 22	62	Males 58%	NR	Sertraline vs. placebo	12 weeks	50 mg/daily for 2 weeks and 100 mg/daily for the remaining 10 weeks
Friedli et al., 2017 [14]	UK	RCT	21 Sertraline: n = 8 Placebo: n = 13	59	Males 76.6%	NR	Sertraline vs. placebo	6 months	50 mg/daily with eventual increase
Zhang et al., 2024 [20]	China	RCT	125 Sertraline: n = 62 Placebo: n = 63	59	Males 52.8%	NR	Sertraline vs. placebo	12 weeks	25–50 mg/daily, then dose adjusted based on patient’s score
Hosseini et al., 2012 [15]	Iran	RCT	44 Citalopram: n = 22 Psychological intervention: n = 22		Males 43%	NR	Citalopram vs. psychological training	12 weeks	20 mg/daily
Mehrotra et al., 2019 [17]	USA	RCT	120 Sertraline: n = 60 CBT: n = 60		Males 57%	NR	Sertraline vs. CBT	12 weeks	25 mg/daily in the first week and 50 mg/daily in the second week. Then, dosage was titrated every 2 weeks for the following 4 weeks until 200 mg/daily, and then, maintained for the following 6 weeks